Terug naar bedrijfspagina

Nieuws over Kiadis Pharma

29/04/2021 KIADIS - Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer (29.04.2021)

27/04/2021 Kiadis - Delisting of Kiadis will be effective on 25 May 2021 (26.4.2021)

07/04/2021 Kiadis 2020 Annual Report (08.04.2021)

22/01/2021 Kiadis - announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR (22.01.2021)

09/12/2020 Kiadis - Sanofi and Kiadis satisfy competition condition related to the tender offer (9.12.2020)

30/11/2020 Kiadis - Update on the intended offer by Sanofi (30.11.2020)

12/11/2020 Kiadis - announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting (12.11.2020)

02/11/2020 Kiadis - Sanofi offers to acquire Kiadis for €308 million (2.11.2020)

30/09/2020 Kiadis - announces results for the six months ended June 30, 2020 (30.9.2020)

28/09/2020 Kiadis - announce collaboration to provide universal donor material for K-NK cell therapy programs (28.9.2020)

15/09/2020 Kiadis - receives $9.5 million from the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program to fund Kiadis K-NK cell COVID-19 therapy (15.9.2020)

14/09/2020 Kiadis - announces U.S. FDA approval for a COVID-19 clinical trial (14.9.2020)

17/08/2020 Kiadis collaborates with premier Dutch institutions

13/07/2020 Kiadis - appoints Ray Barlow as Chief Business Officer and Govert Schouten as Head of Innovation (13.7.2020)

08/07/2020 Kiadis - licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi (8.7.2020)

26/05/2020 Kiadis - to present at the Jefferies 2020 Healthcare Conference (26.5.2020)

13/05/2020 Kiadis Pharma - announces new data validating and enhancing its PM21 K-NK-cell platform (13.5.2020)

06/05/2020 Kiadis Pharma kondigt goedkeuring van Amerikaanse FDA aan voor start van NK-REALM Fase 2-klinische studie (6.5.2020)

29/04/2020 Kiadis Pharma - maakt donderdag 30 april 2020 de jaarcijfers bekend over het jaar 2019 (28.4.2020)

28/04/2020 Kiadis Pharma - haalt €12 miljoen financiering op door onderhandse plaatsing van aandelen bij een Amerikaanse biotech investeerder (28.4.2020).

10/03/2020 Kiadis Pharma - announces new data on ex-vivo FC21 expanded NK-cell therapy (10.3.2020)

26/02/2020 Kiadis Pharma announces -FDA clearance of clinical study by The Ohio State University (26.2.2020)

14/11/2019 Kiadis Pharma - changes strategy to focus solely on development of Natural Killer (12.11.2019)

06/11/2019 Kiadis Pharma to present at the American Society of Hematology 2019 Annual Meeting (6.11.2019)

10/09/2019 Kiadis Pharma - announces results for the six months ended June 30 (10.9.2019)

29/07/2019 Kiadis (KBC)

06/06/2019 Kiadis Pharma - completes acquisition of CytoSen Therapeutics (6.6.2019)

03/06/2019 Kiadis Pharma (Jefferies)

23/05/2019 Kiadis (Jefferies)

22/05/2019 Kiadis - Submits Response to the European Medicines Agency's Day 180 Second List of Outstanding Issues (22.5.2019)

22/05/2019 Kiadis - Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration to Accelerate Patient Access to Haploidentical Stem Cell Therapies (22.5.2019)

30/04/2019 Kiadis Pharma - annual results for the year ended December 31, 2018 (30.4.2019)

17/04/2019 Kiadis to Acquire CytoSen Therapeutics (17.4.2019)

01/03/2019 Kiadis Pharma to present at upcoming investor conferences in March 2019 (1.3.2019)

15/02/2019 Kiadis-Pharma-NV-EGM-29-03-2019-notice-agenda-and-explanatory (15.2.2019)

11/02/2019 Kiadis Pharma to participate in a panel at Innovation for Health 2019 (11.2.2019)

11/02/2019 Kiadis Pharma to participate in a panel at Innovation for Health 2019 (11.2.2019)

05/02/2019 Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer (5.2.2019)

04/01/2019 Kiadis Pharma expands presence in the United States (4.1.2019)

03/01/2019 Kiadis Pharma to present at biotecch showcase 2019 ( 3.1.2019)

13/11/2018 Kiadis Pharma to present at upcoming investor conferences in November 2018 (13.11.2018

08/11/2018 Kiadis Pharma strengthens core team with three senior appointments (8.11.2018)

07/11/2018 Kiadis Pharma announces abstracts and presentations for the 60th American Society of Hematology (7.11.2018)

19/10/2018 Kiadis Pharma raises €31.2 million in a private placement of 3.9 million new shares (19.10.2018)

18/10/2018 Kiadis Pharma launches a private placement of approximately 3.7 million new shares (18.10.2018)

12/10/2018 Kiadis (Jefferies)

12/10/2018 Kiadis Pharma provides regulatory and clinical update on ATIR101

26/09/2018 Kiadis (Jefferies)

04/09/2018 Kiadis Remains on Track for CHMP Decision Regarding ATIR101 in Q4 2018 (4.9.218)

31/08/2018 Kiadis (Jefferies)

31/08/2018 Kiadis-Pharma-Interim-Report-H1-2018 (31.8.2018)

30/08/2018 Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer (30.8.2018)

24/08/2018 Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018 (24.8.2018)

16/04/2018 Kiadis (Jefferies)

14/03/2018 Kiadis Pharma : Extra ademruimte (KBC Group)

01/02/2018 Kiadis (LifeSci Capital)

16/06/2016 2016 06 - Interview met ceo Manfred Rüdiger

03/06/2016 Bolero: Kiadis Pharma; Tempoversnelling